{"id":826,"date":"2017-02-14T09:02:23","date_gmt":"2017-02-14T08:02:23","guid":{"rendered":"https:\/\/old.intervacc.se\/en\/?page_id=826"},"modified":"2017-02-14T09:02:23","modified_gmt":"2017-02-14T08:02:23","slug":"nya-generationens-vacciner-eng","status":"publish","type":"page","link":"https:\/\/old.intervacc.se\/en\/arkiv-gamla-texter-eng\/nya-generationens-vacciner-eng\/","title":{"rendered":"Nya generationens vacciner (eng)"},"content":{"rendered":"<div style=\"text-align: justify;\">\n<div class=\"preamble\">\n<p>(eng)<\/p>\n<p>Intervacc AB \u00e4r ett svenskt bolag verksamt inom Biotekniksektorn. F\u00f6r att m\u00f6ta det \u00f6kande behovet av effektiva vacciner inom djurh\u00e4lsov\u00e5rden utvecklar Intervacc nya vacciner baserade p\u00e5 rekombinanta proteiner.<\/p>\n<\/div>\n<p><img loading=\"lazy\" class=\"size-body-thumbnail wp-image-209 alignnone\" src=\"https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body1-170x134.png\" alt=\"\" width=\"170\" height=\"134\" srcset=\"https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body1-170x134.png 170w, https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body1-300x237.png 300w, https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body1.png 338w\" sizes=\"(max-width: 170px) 100vw, 170px\" \/> <img loading=\"lazy\" class=\"alignnone wp-image-208 size-body-thumbnail\" src=\"https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body-3-170x134.png\" width=\"170\" height=\"134\" srcset=\"https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body-3-170x134.png 170w, https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body-3-300x236.png 300w, https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body-3.png 339w\" sizes=\"(max-width: 170px) 100vw, 170px\" \/>\u00a0 <img loading=\"lazy\" class=\"alignnone wp-image-207 size-body-thumbnail\" src=\"https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body-2-170x134.png\" width=\"170\" height=\"134\" srcset=\"https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body-2-170x134.png 170w, https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body-2-300x236.png 300w, https:\/\/old.intervacc.se\/wp-content\/uploads\/2016\/06\/front-body-2.png 339w\" sizes=\"(max-width: 170px) 100vw, 170px\" \/><\/p>\n<p>Teknologiplattformen baseras p\u00e5 forskning vid Karolinska Institutet och Sveriges Lantbruksuniversitet. Fokus ligger i f\u00f6rsta hand p\u00e5 utvecklingen av Bolagets f\u00f6rsta vaccinkandidat, Strangvac\u00ae, som \u00e4r ett vaccin mot kvarka som orsakas av Streptococcus equi. Strangvac\u00ae har visat god dokumenterad skyddseffekt mot en sjukdom som hittills saknat ett b\u00e5de <a href=\"#\">s\u00e4kert<\/a> och effektivt vaccin.<\/p>\n<p>&nbsp;<\/p>\n<ul class=\"list-style\">\n<li>Intervacc \u00e4r ett publikt bolag med drygt 180 aktie\u00e4gare.<\/li>\n<li>Forskargruppen tillsammans med <a href=\"#\">Nordvacc L\u00e4kemedel Holding<\/a>, Knutsson Holdings och Lyftet Holdings representerar de st\u00f6rre \u00e4garna.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>(eng) Intervacc AB \u00e4r ett svenskt bolag verksamt inom Biotekniksektorn. F\u00f6r att m\u00f6ta det \u00f6kande behovet av effektiva vacciner inom djurh\u00e4lsov\u00e5rden utvecklar Intervacc nya vacciner baserade p\u00e5 rekombinanta proteiner. \u00a0 Teknologiplattformen baseras p\u00e5 forskning vid Karolinska Institutet och Sveriges Lantbruksuniversitet. Fokus ligger i f\u00f6rsta hand p\u00e5 utvecklingen av Bolagets f\u00f6rsta vaccinkandidat, Strangvac\u00ae, som \u00e4r ett [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":825,"menu_order":110,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false},"_links":{"self":[{"href":"https:\/\/old.intervacc.se\/en\/wp-json\/wp\/v2\/pages\/826"}],"collection":[{"href":"https:\/\/old.intervacc.se\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/old.intervacc.se\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/old.intervacc.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/old.intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=826"}],"version-history":[{"count":1,"href":"https:\/\/old.intervacc.se\/en\/wp-json\/wp\/v2\/pages\/826\/revisions"}],"predecessor-version":[{"id":832,"href":"https:\/\/old.intervacc.se\/en\/wp-json\/wp\/v2\/pages\/826\/revisions\/832"}],"up":[{"embeddable":true,"href":"https:\/\/old.intervacc.se\/en\/wp-json\/wp\/v2\/pages\/825"}],"wp:attachment":[{"href":"https:\/\/old.intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}